The global personalized antigen oncology therapeutic sector is currently experiencing a turbulent period of advancement, fueled by significant progress in personalized medicine and a growing understanding of the immune system's capability in combating cancers. Predictions indicate a sustained expansion in the future years, driven by clinical trials